Previous Next


№1' 2020


International Medical Journal, Vol. 26., Iss. 1, 2020, P. 39−41.



Sadchikova M. V., Syniavina L. V., Otchenash N. M.

Kharkiv Medical Academy of Postgraduate Education
Communal Non−Profit Institution Regional Center of Oncology, Kharkiv
Eva Medical Center, Kharkiv, Ukraine

It is known that a complete recovery in patients with generalized tumor is impossible, but the use of effective treatment regimens can significantly inhibit the development of the disease. The main goal of treatment of metastatic breast cancer is to increase overall survival, time to disease progression, improvethe quality of life, to prevent serious complications. In recent years, the standard of first−line hormone therapy in postmenopausal patients has been the use of aromatase inhibitors. Recently, a new class of drugs has emerged that can increase the effectiveness of hormone therapy, which significantly strengthens the position of this method in metastatic breast cancer. A clinical trial of PALOMA−2 and its findings are presented: the palbociclib + letrozole protocol as first−line therapy in postmenopausal patients with estrogen−positive Her2 new negative advanced breast cancer improves the objective response rate and clinical efficacy compared to letrozole monotherapy. The overall incidence of adverse responses was higher in patients treated with palbociclib + letrozole compared with placebo + letrozole. This clinical case demonstrates the possibility of long−term effective disease control in metastatic breast cancer. Literature data and personal experience show high efficacy of the combined protocol of hormone therapy and inhibitors of cyclin−dependent kinases 4/6. The use of such protocols is advisable in patients with multiple bone metastases, while achieving an effective reduction of pain. The use of such regimens is possible in patients with a low ECOG score who cannot tolerate chemotherapy with more severe toxicity.

Key words: metastatic breast cancer, aromatase inhibitors, palbociclib.


1. Rak v Ukraїnі, 2017−2018. Byuleten' Natsіonal'nogo kantser−reєstru № 20. S. 46−47.

2. Wilcken N., Hornbuckle J., Ghersi D. Chemotherapy alone versus endocrine therapy alone for metastatic breast cancer // Cochrane Database Syst. Rev. 2003. Vol. 2. doi:

3. PD 0332991, a selective cyclin D kinase 4/6 inhibitor, preferentially inhibits proliferation of luminal estrogen receptor−positive human breast cancer cell lines in vitro / R. S. Finn et al. // Breast Cancer Res. 2009. Vol. 11 (5). R. 77. doi:

4. Palbociclib and letrozole in advanced breast cancer / R. S. Finn et al. // N. Engl. J. Med. 2016. Vol. 375. R. 1925−36.

5. Palbociclib in hormone−receptor−positive advanced breast cancer / N. C. Turner et al. // N. Engl. J. Med. 2015. Vol. 373. R. 209−219.

6. Palbociclib (PAL) + letrozole (LET) as first−line therapy in estrogen receptor−positive (ER+)/human epidermal growth factor receptor 2−negative (HER2−) advanced breast cancer (ABC): Efficacy and safety updates with longer follow−up across patient subgroups / H. S. Rugo et al. // Presented at SABCS 2017, San Antonio, Texas, USA. Abstr. P. 5−21−03. doi:−7445.sabcs17−p5−21−03

7. Impact of palbociclib plus letrozole on patient−reported health−related quality of life: results from the PALOMA−2 trial / H. S. Rugo et al. // Ann. Oncol. 2018. Vol. 29. R. 888−894. doi:

Go on Top